Strategies to optimize the brain availability of central nervous system drug candidates
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Access to the CNS is essential for most neurotherapeutics to elicit their effects. Leveraging design strategies incorporating physicochemical properties, in vitro and in vivo assays to predict and measure brain penetration, and brain delivery approaches may enable the drug discovery community to improve access of drug candidates into the CNS compartment. AREAS COVERED: This article reviews aspects of the most recent molecular design, in vitro and in vivo strategies, and delivery technologies to optimize the unbound brain concentrations (C (b,u)) of CNS molecules. Through this, the article provides insight into recent ideas and concepts in CNS drug molecule design, methods for evaluating CNS drug exposures and alternative approaches to maximize drug access to neurocompartments. EXPERT OPINION: The most pharmacologically relevant measure in assessing a compound's pharmacodynamic response in the CNS is its C (b,u). The utilization of emerging design strategies, together with in vitro and in vivo assays, may enable the design of molecules with optimal C (b,u):C (p,u) (C (p,u), unbound plasma concentration) and appropriate C (b,u,) to elicit a biological response from the neurotherapeutic target. Where drug properties intrinsically render a compound CNS impaired, using novel CNS delivery approaches may result in sufficient C (b,u) to furnish a biological response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., et al. (2009) · Science · doi:10.1126/science.1168750 · Cited by 1,929 · cited 1×
“The recent publication of the X-ray crystal structure of mouse P-gp, which has 87% sequence homology with human P-gp, provides a new opportunity to elucidate the function and mechanism of this transporter [46].”
BackgroundClinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
CNS Drug Delivery Systems: Novel Approaches
Pathan, S., Iqbal, Z., Zaidi, S., Talegaonkar, S., Vohra, D., Jain, G., Azeem, A., Jain, N., Lalani, J., Khar, R., et al. (2009) · Recent Patents on Drug Delivery & Formulation · doi:10.2174/187221109787158355 · Cited by 193 · cited 1×
“Numerous approaches are under investigation to identify novel ways of getting therapeutics into the brain for biological targets requiring compounds that cannot passively enter the central compartment due to efflux and/or undesirable physicochemical properties [63].”
BackgroundThakker, D. R., Weatherspoon, M. R., Harrison, J., Keene, T. E., Lane, D. S., Kaemmerer, W. F., Stewart, G. R., & Shafer, L. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813404106 · Cited by 124 · cited 2×
“More importantly, this approach appears to have significantly lower cerebral amyloid angiopathy associated with micro-hemorrhages, providing a potential improvement in the treatment of AD [73].”
Background
Cited by
Ghose, A. K., Herbertz, T., Hudkins, R. L., Dorsey, B. D., & Mallamo, J. P. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200100h · Cited by 447
Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need
Field, M. C., Horn, D., Fairlamb, A. H., Ferguson, M. A. J., Gray, D. W., Read, K. D., De Rycker, M., Torrie, L. S., Wyatt, P. G., Wyllie, S., et al. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.193 · Cited by 421
Raub, T. J., Wishart, G. N., Kulanthaivel, P., Staton, B. A., Ajamie, R. T., Sawada, G. A., Gelbert, L. M., Shannon, H. E., Sanchez-Martinez, C., & De Dios, A. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.062745 · Cited by 284
“The unbound brain concentration is the most relevant parameter in assessing the pharmacodynamic response of a CNS agent (Wager et al., 2011).”
BackgroundInfluentialWhy Are the Majority of Active Compounds in the CNS Domain Natural Products? A Critical Analysis
Bharate, S. S., Mignani, S., & Vishwakarma, R. A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01922 · Cited by 102
Bueters, T., Ploeger, B. A., & Visser, S. A. G. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.001 · Cited by 43
Metadata
- Authors
- Wager, T. T., Villalobos, A., Verhoest, P. R., Hou, X., & Shaffer, C. L.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa Healthcare
- Published
- 2011-03-22
- Volume
- 6
- Issue
- 4
- Pages
- 371-381
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W2054976145
- Cited by
- 52
- References
- 6
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Strategies to optimize the brain availability of central nervous system drug candidates. https://app.cochat.ai/papers/10.1517/17460441.2011.564158
- The paper
- Wager, T. T., Villalobos, A., Verhoest, P. R., Hou, X., & Shaffer, C. L. (2011). Strategies to optimize the brain availability of central nervous system drug candidates. Expert Opinion on Drug Discovery. https://doi.org/10.1517/17460441.2011.564158
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.